Apimeds Pharmaceuticals US (APUS) Interest Coverage Ratio (2024 - 2025)
Apimeds Pharmaceuticals US (APUS) posted Interest Coverage Ratio of 25.29 for Q4 2025, up 91.36% on a QoQ basis from 292.69 in Q3 2025, and down 893.43% year-over-year from 3.19 in Q4 2024.
Apimeds Pharmaceuticals US (APUS) Interest Coverage Ratio (2024 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US's Interest Coverage Ratio history runs 2 years deep, the most recent figure standing at 25.29 for Q4 2025.
- Quarterly Interest Coverage Ratio fell 893.43% year-over-year to 25.29 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 34.45 (down 413.19% YoY) and the FY2025 annual result came in at 4.5, down 302.94% from the prior year.
- Interest Coverage Ratio was 25.29 for Q4 2025 at Apimeds Pharmaceuticals US, up from 292.69 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2.55 in Q4 2024 and bottomed at 292.69 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | Apimeds Pharmaceuticals US | 8.17 Mn | 8.17 Mn | - | -25.29 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -25.29 |
| Sep 30, 2025 | -292.69 |
| Jun 30, 2025 | -115.55 |
| Mar 31, 2025 | -9.58 |
| Dec 31, 2024 | -2.55 |
| Sep 30, 2024 | -9.19 |
| Jun 30, 2024 | -19.34 |
| Mar 31, 2024 | -10.10 |